{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.3","value":"14.5"},{"groupId":"OG001","spread":"1.8","value":"14.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"HRQL was measured by the Functional Assessment of Cancer Therapy Breast Symptom Index (FBSI) Treatment Side Effects (TSE) subscale score, an aggregate score of 4 items (GP2, GP5, N6 and B5) from the FBSI-16 scale. The FBSI TSE subscale score was calculated based on the scoring manual, score ranges from 0 to 16, higher scores indicate better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV","id":"OG000","title":"Arm B (Cisplatin or Carboplatin)"},{"description":"Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO","id":"OG001","title":"Arm C (Capecitabine) (Open to Accrual 6/22/2016)"}],"paramType":"MEAN","populationDescription":"All patients randomized to arms B and C and reported health-related quality of life data at 15-month assessment","reportingStatus":"POSTED","timeFrame":"Assessed at 15 months after randomization","title":"Health-related Quality of Life (HRQL) at 15-month Assessment","type":"SECONDARY","unitOfMeasure":"score on a scale"}